Literature DB >> 21277438

Early versus delayed treatment of relapsed ovarian cancer.

Gordon Rustin, Maria van der Burg, Clare Griffin, Wendi Qian, Ann Marie Swart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21277438     DOI： 10.1016/S0140-6736(11)60126-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  30 in total

1.  Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.

Authors:  Seiya Sato; Hiroaki Itamochi
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

Review 2.  Health-related quality of life in ovarian cancer patients and its impact on clinical management.

Authors:  Dana M Chase; Lari Wenzel
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-08       Impact factor: 2.217

3.  Clinical significance of RAD51C and its contribution to ovarian carcinogenesis.

Authors:  Xiao-Li Lu; Si-Sun Liu; Zhen-Fang Xiong; Fen Wang; Xia-Ying Li; Huan Deng
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

4.  UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis.

Authors:  Yijun Yang; Yi Jiang; Yicong Wan; Lin Zhang; Jiangnan Qiu; Shulin Zhou; Wenjun Cheng
Journal:  Tumour Biol       Date:  2016-02-11

Review 5.  Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.

Authors:  Helena J Janse van Rensburg; Pavlina Spiliopoulou; Lillian L Siu
Journal:  Oncologist       Date:  2022-05-06       Impact factor: 5.837

Review 6.  AFAP1-AS1: A novel oncogenic long non-coding RNA in human cancers.

Authors:  Fuyou Zhang; Jianfa Li; Huizhong Xiao; Yifan Zou; Yuchen Liu; Weiren Huang
Journal:  Cell Prolif       Date:  2017-10-22       Impact factor: 6.831

Review 7.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Authors:  David D Bowtell; Steffen Böhm; Ahmed A Ahmed; Paul-Joseph Aspuria; Robert C Bast; Valerie Beral; Jonathan S Berek; Michael J Birrer; Sarah Blagden; Michael A Bookman; James D Brenton; Katherine B Chiappinelli; Filipe Correia Martins; George Coukos; Ronny Drapkin; Richard Edmondson; Christina Fotopoulou; Hani Gabra; Jérôme Galon; Charlie Gourley; Valerie Heong; David G Huntsman; Marcin Iwanicki; Beth Y Karlan; Allyson Kaye; Ernst Lengyel; Douglas A Levine; Karen H Lu; Iain A McNeish; Usha Menon; Steven A Narod; Brad H Nelson; Kenneth P Nephew; Paul Pharoah; Daniel J Powell; Pilar Ramos; Iris L Romero; Clare L Scott; Anil K Sood; Euan A Stronach; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

8.  Hypoxia inducible factor 1α-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer.

Authors:  Fang Ji; You Wang; Lihua Qiu; Shu Li; Jing Zhu; Zhou Liang; Yinsheng Wan; Wen Di
Journal:  Int J Oncol       Date:  2013-03-29       Impact factor: 5.650

9.  Long non-coding RNA ADAMTS9-AS1 attenuates ferroptosis by Targeting microRNA-587/solute carrier family 7 member 11 axis in epithelial ovarian cancer.

Authors:  Li Cai; Xiaoqing Hu; Lu Ye; Pingjuan Bai; Youkun Jie; Kuanyong Shu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

10.  LncRNA ARAP1-AS1 aggravates the malignant phenotypes of ovarian cancer cells through sponging miR-4735-3p to enhance PLAGL2 expression.

Authors:  Cuiping Li; Bing Dong; Xiaomeng Xu; Yuewen Li; Yan Wang; Xingmei Li
Journal:  Cytotechnology       Date:  2021-04-03       Impact factor: 2.040
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.